Q4 2020 Arcticzymes Technologies ASA Earnings Call Transcript
Okay. We'll make a start then. So welcome to the Q4 presentation. Both Børge Sørvoll, our CFO; and I, Jethro Holter, the CEO, will walk you through the presentation today. (Operator Instructions) At the end of the presentation, we will open up for questions. (Operator Instructions)
So the agenda today is we're going to start by going through the highlights of Q4. We will then tell you a little bit about the deliverables we delivered on in 2020. We will then go through the ArcticZymes update. We'll briefly talk about the Biotec BetaGlucans divestments. Børge will walk you through the Q4 financials, then I'll round off by talking about the outlook for 2021 and beyond.
Now before we go into all the details, I do want to say that all the figures and numbers that are presented today are excluding discontinued operations, which is the Biotec BetaGlucans business.
So highlights. So in a nutshell, as a company, what we've seen during 2020 is that the company has undergone a significant transformation. And this is no exception in Q4
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |